Abnormal activation of PI3K/Akt and Wnt/β-catenin pathways has been found to promote GC progression and poor prognosis of cancer patients, suggesting their potential therapeutic target for GC patients [11,53,54,55]. The gene discussed is AKT1; the disease is gastric cancer.